These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122 [TBL] [Abstract][Full Text] [Related]
25. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065 [TBL] [Abstract][Full Text] [Related]
26. High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma. Masaki Y; Miki M; Sun Y; Nakamura T; Iwao H; Nakajima A; Kurose N; Sakai T; Jin ZX; Sawaki T; Kawanami T; Fujita Y; Tanaka M; Fukushima T; Hirose Y; Umehara H Int J Hematol; 2011 Jun; 93(6):720-726. PubMed ID: 21573892 [TBL] [Abstract][Full Text] [Related]
27. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989 [TBL] [Abstract][Full Text] [Related]
29. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772 [TBL] [Abstract][Full Text] [Related]
30. Characterizing second line and beyond therapies for primary central nervous system lymphomas. Primeaux B; Luo C; Yeung EK; Linger C; Chen S; Do B Hematol Oncol; 2024 Nov; 42(6):e3313. PubMed ID: 39340121 [TBL] [Abstract][Full Text] [Related]
31. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443 [TBL] [Abstract][Full Text] [Related]
32. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Yu J; Du H; Ye X; Zhang L; Xiao H Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528 [TBL] [Abstract][Full Text] [Related]
33. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
34. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China. Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418 [TBL] [Abstract][Full Text] [Related]
35. Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Batchelor TT; Giri S; Ruppert AS; Geyer SM; Smith SE; Mohile N; Swinnen LJ; Friedberg JW; Kahl BS; Bartlett NL; Hsi ED; Cheson BD; Wagner-Johnston N; Nayak L; Leonard JP; Rubenstein JL Blood Adv; 2024 Jun; 8(12):3189-3199. PubMed ID: 38598710 [TBL] [Abstract][Full Text] [Related]
36. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E Oncology; 2001; 60(2):134-40. PubMed ID: 11244328 [TBL] [Abstract][Full Text] [Related]
37. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986 [TBL] [Abstract][Full Text] [Related]
38. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853 [TBL] [Abstract][Full Text] [Related]
39. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429 [TBL] [Abstract][Full Text] [Related]
40. New approaches in primary central nervous system lymphoma. Fraser E; Gruenberg K; Rubenstein JL Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]